The efficacy of Femal in women with premenstrual syndrome: a randomised, double-blind, parallel-group, placebo-controlled, multicentre study

被引:16
|
作者
Gerhardsen, Gerhard [1 ]
Hansen, Anne V. [2 ]
Killi, Marianne [3 ]
Fornitz, Gitte Gleerup [4 ]
Pedersen, Frank [5 ]
Roos, Signe Barfod [6 ,7 ]
机构
[1] Greverud Legesenter, Oppegard 1415, Norway
[2] Univ Copenhagen, Fac Life Sci, Copenhagen, Denmark
[3] Fartein Valens Vej 45, Kolbotn, Norway
[4] Amager Hosp, Med Ctr, Copenhagen, Denmark
[5] Herning Hosp, Herning, Denmark
[6] Kommune Hosp Copenhagen, Dept Clin Biochem, Gentofte, Denmark
[7] Univ Copenhagen, Hellerup, Denmark
关键词
herbal medicinal product; pollen; premenstrual syndrome; sleep disturbance;
D O I
10.1007/s12325-008-0072-4
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Introduction: A double-blind, placebo-controlled, randomised, parallel-group, multicentre study was conducted to evaluate the effect of a pollen-based herbal medicinal product, Femal (R) (Sea-Band Ltd, Leicestershire, UK), on premenstrual sleep disturbances (PSD) in women with premenstrual syndrome (PMS). Methods: Femal, 160 mg twice-daily, was given for four menstrual cycles to 50 women, and placebo to 51 women. PSD were evaluated on a visual analogue scale prior to and after the four cycles. The effect on overall PMS symptoms was assessed with the Steiner premenstrual tension syndrome (PMTS) self-rating questionnaire. The results were analysed statistically based on intention to treat. Results: Femal treatment resulted in a significant reduction in PSD (P < 0.05) whereas placebo had no significant effect (P > 0.05). In a subgroup analysis of women with irritability as their main PMS symptom cluster, the reduction of PSD was even more pronounced (P < 0.001). There was no significant difference in overall degree of PMS symptom reduction between Femal and placebo when all participating women were evaluated (P > 0.05). However, in women with irritability as their main PMS symptom cluster, Femal treatment resulted in a significant reduction of the Steiner score (P < 0.05). The frequency of adverse events was not significantly different in women on Femal compared to women on placebo (P > 0.05). No serious adverse events were recorded. Conclusions: Femal treatment reduced PSD to a significant degree, particularly in women with irritability as their main PMS symptom. Femal treatment also reduced overall PMS symptoms in women with irritability (but not dysphoria) as their main PMS symptom. The safety of Femal and its efficacy in PSD and other symptoms in women with irritability as the main symptom cluster makes this herbal medicinal product a promising addition to the therapeutic arsenal for women with PMS.
引用
收藏
页码:595 / 607
页数:13
相关论文
共 50 条
  • [21] LX9211 in individuals with painful diabetic peripheral neuropathy: results from a randomised, double-blind, placebo-controlled, parallel-group, multicentre study
    Pop-Busui, R.
    Patel, A.
    Sang, C.
    Granowitz, C.
    Banks, P.
    Pierce, P.
    Sun, F.
    Gopinathan, S.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S17 - S18
  • [22] Transdermal selegiline in major depression: A double-blind, placebo-controlled, parallel-group study in outpatients
    Bodkin, JA
    Amsterdam, JD
    AMERICAN JOURNAL OF PSYCHIATRY, 2002, 159 (11): : 1869 - 1875
  • [23] Lamotrigine for painful polyneuropathy: Randomized, placebo-controlled, double-blind, parallel-group pilot study
    Hart, DE
    Riback, PS
    Calder, CS
    Storey, JR
    Wymer, JP
    Potter, DL
    ANNALS OF NEUROLOGY, 2001, 50 (03) : S35 - S35
  • [24] Efficacy of Quadruple-coated Probiotics in Patients With Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled, Parallel-group Study
    Chang, Young Hoon
    Choi, Yoon Jin
    Shin, Cheol Min
    Moon, Jin Seok
    Kim, Tae-Yoon
    Yoon, Hyuk
    Park, Young Soo
    Kim, Nayoung
    Lee, Dong Ho
    JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY, 2024, 30 (01) : 73 - 86
  • [25] Effects of rhamnose consumption on bone mineral density in healthy postmenopausal women: a randomised, placebo-controlled, double-blind, parallel-group pilot study
    Suzuki, Naoko
    Imada, Takafumi
    Ueshima, Naoki
    Orikoshi, Hideyuki
    Takara, Tsuyoshi
    INTERNATIONAL JOURNAL OF FOOD SCIENCES AND NUTRITION, 2024, 75 (07) : 717 - 728
  • [26] Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial
    Kapoor, Raju
    Furby, Julian
    Hayton, Thomas
    Smith, Kenneth J.
    Altmann, Daniel R.
    Brenner, Robert
    Chataway, Jeremy
    Hughes, Richard A. C.
    Miller, David H.
    LANCET NEUROLOGY, 2010, 9 (07): : 681 - 688
  • [27] Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial
    Goudie, Andrew R.
    Lipworth, Brian J.
    Hopkinson, Pippa J.
    Wei, Li
    Struthers, Allan D.
    LANCET RESPIRATORY MEDICINE, 2014, 2 (04): : 293 - 300
  • [28] Patiromer utility as an adjunct treatment in patients needing urgent hyperkalaemia management (PLATINUM): design of a multicentre, randomised, double-blind, placebo-controlled, parallel-group study
    Rafique, Zubaid
    Budden, Jeffrey
    Quinn, Carol Moreno
    Duanmu, Youyou
    Safdar, Basmah
    Bischof, Jason J.
    Driver, Brian E.
    Herzog, Charles A.
    Weir, Matthew R.
    Singer, Adam J.
    Boone, Stephen
    Soto-Ruiz, Karina M.
    Peacock, W. Frank
    BMJ OPEN, 2023, 13 (06):
  • [29] Efficacy and safety of GQ-lab daily in patients with irritable bowel syndrome: A randomized, double-blind, placebo-controlled, parallel-group study
    Shin, C. M.
    Choi, Y. J.
    Yoon, H.
    Park, Y. S.
    Kim, N.
    Lee, D. H.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2019, 31
  • [30] A DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY OF LACTULOSE IN THE TREATMENT OF ENCOPRESIS IN CHILDREN WITH CHRONIC CONSTIPATION
    GLEASON, W
    FIGUEROACOLON, R
    ROBINSON, LH
    BROWDERHUGHES, S
    PHILLIPS, R
    FLEISHMAN, C
    FRANK, D
    NESTER, T
    GASTROENTEROLOGY, 1995, 108 (04) : A606 - A606